We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Weight-Adjusted Dosing of 3-OHB in Patients With Chronic Heart Failure (KINETICS2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04594265
Recruitment Status : Recruiting
First Posted : October 20, 2020
Last Update Posted : July 18, 2022
Sponsor:
Information provided by (Responsible Party):
Kristian Hylleberg Christensen, Aarhus University Hospital

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
We aim to investigate the hemodynamic effects of weight-adjusted dosing of ketone monoester en patients with chronic heart failure.

Condition or disease Intervention/treatment Phase
Heart Failure Ketosis Dietary Supplement: KetoneAid KE4 Pro Monoester Dietary Supplement: Science in Sport Go Enegy Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 8 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Patients are studied in a randomized single-blind cross-over design.
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Weight-Adjusted Dosing of 3-OHB in Patients With Chronic Heart Failure
Actual Study Start Date : October 1, 2020
Estimated Primary Completion Date : September 30, 2022
Estimated Study Completion Date : September 30, 2022

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Ketone Monoester
Weight-adjusted dose of 3-OHB Monoester (KetoneAID KE4, Virginia, US) 0.5 g/kg (max 50 g)
 Dietary Supplement: KetoneAid KE4 Pro Monoester
A dietary supplement containing ketone monoester.
Placebo Comparator: Placebo Treatment
Maltodextrin-based placebo (Science In Sport, UK) in isocaloric dose to the experimental arm.
 Dietary Supplement: Science in Sport Go Enegy
Dosis isocaloric to the KetoneAid Arm
Active Comparator: Ketone Monoester in presence of low-dose insulin clamp
Same as experimental arm, but in the presence of a low-dose insulin clamp to suppress free fatty acid metabolism
 Dietary Supplement: KetoneAid KE4 Pro Monoester
A dietary supplement containing ketone monoester.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Cardiac Output (L/min) [ Time Frame: 3 hours - Area under the curve ]
    Change in Cardiac output measured by Swann-Ganz Catherization during study period,


Secondary Outcome Measures :
  1. Left Ventricular Ejection Fraction [ Time Frame: 3 hours - Area under the curve ]
    Change in LVEF measured by echocardiography during study periode

  2. Blood Ketones [ Time Frame: 3 hours ]
    Change in blood Ketones measured by venous blood samples

  3. Blood pH [ Time Frame: 3 hours ]
    Change in venous blood pH during the study period


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria: Chronic HF: NYHA class II-III, left ventricular ejection fraction (LVEF) <40%

Exclusion Criteria: Diabetes or HbA1c >48 mmol/mol, significant cardiac valve disease, severe stable angina pectoris, severe comorbidity as judged by the investigator, inability to give informed consent

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04594265


Contacts
Layout table for location contacts
Contact: Kristian H Christensen, MD +4578452029 krstchri@rm.dk
Contact: Henrik S Wiggers, DMsci

Locations
Layout table for location information
Denmark
Aarhus University Hospital Recruiting
Aarhus, Denmark, 8200
Contact: Kristian H Christensen, MD       krstchri@rm.dk   
Sponsors and Collaborators
University of Aarhus
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Kristian Hylleberg Christensen, MD, Aarhus University Hospital
ClinicalTrials.gov Identifier: NCT04594265    
Other Study ID Numbers: KETO-KINETICS 2 1-10-72-23-20
First Posted: October 20, 2020    Key Record Dates
Last Update Posted: July 18, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Kristian Hylleberg Christensen, Aarhus University Hospital:
Hemodynamics
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases